These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17470153)

  • 1. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.
    Matsumoto A; Haraguchi K; Takahashi T; Azuma T; Kanda Y; Tomita K; Kurokawa M; Ogawa S; Takahashi K; Chiba S; Kitamura T
    Int J Urol; 2007 Apr; 14(4):277-83. PubMed ID: 17470153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
    Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
    J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
    Höltl L; Zelle-Rieser C; Gander H; Papesh C; Ramoner R; Bartsch G; Rogatsch H; Barsoum AL; Coggin JH; Thurnher M
    Clin Cancer Res; 2002 Nov; 8(11):3369-76. PubMed ID: 12429623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
    Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
    Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
    Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
    Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study.
    Ovali E; Dikmen T; Sonmez M; Yilmaz M; Unal A; Dalbasti T; Kuzeyli K; Erturk M; Omay SB
    J Exp Clin Cancer Res; 2007 Jun; 26(2):209-14. PubMed ID: 17725100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
    Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma.
    Tatsugami K; Eto M; Harano M; Hamaguchi M; Miyamoto T; Morisaki T; Furue M; Akashi K; Naito S
    Int J Urol; 2008 Aug; 15(8):694-8. PubMed ID: 18564205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
    Hegmans JP; Veltman JD; Lambers ME; de Vries IJ; Figdor CG; Hendriks RW; Hoogsteden HC; Lambrecht BN; Aerts JG
    Am J Respir Crit Care Med; 2010 Jun; 181(12):1383-90. PubMed ID: 20167848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
    Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
    J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
    Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience.
    Azuma T; Horie S; Tomita K; Takahashi T; Tanaka Y; Kashiwase K; Nieda M; Takeuchi T; Ohta N; Shibata Y; Hirai H; Kitamura T
    Int J Urol; 2002 Jun; 9(6):340-6. PubMed ID: 12110099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
    Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
    Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.